tradingkey.logo

bluebird bio Inc <BLUE.OQ> expected to post a loss of $3.69 a share - Earnings Preview

ReutersMay 5, 2025 1:07 PM
  • bluebird bio Inc BLUE.OQ BLUE.O is expected to show a rise in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025

  • The Somerville Massachusetts-based company is expected to report a 104.1% increase in revenue to $37.9 million from $18.57 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for bluebird bio Inc is for a loss of $3.69 per share.

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts had risen by about 0.6% in the last three months. ​

  • Wall Street's median 12-month price target for bluebird bio Inc is $8.00​, above​ its last closing price of $3.95. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-5.13

-5.98

-2.95

Beat

50.6

Sep. 30 2024

-6.65

-7.29

-6.20

Beat

14.9

Jun. 30 2024

-9.96

-8.33

-8.40

Missed

-0.8​

Mar. 31 2024

-8.83

-8.81

-7.20

Beat

18.3

​​Dec. 31 2023

-13.01

-13.24

-15.60

Missed

-17.8

Sep. 30 2023

-13.45

-13.50

-13.20

Beat

2.2​

Jun. 30 2023

-14.37

-14.31

-13.40

Beat

6.4

Mar. 31 2023

-5.37

-7.40

4.20

Beat

156.8

This summary was machine generated May 5 at 13:07 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI